Global Neuroendocrine Carcinoma Market Size Projected to Reach $2.31 Billion During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

By How Much Is The Neuroendocrine Carcinoma Market Expected To Expand Between 2025 And 2029?

The neuroendocrine carcinoma market size has seen substantial growth recently. It is anticipated to expand from $1.63 billion in 2024 to $1.75 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 7.4%. This historic expansion was driven by factors such as the development of the imaging sector, a rise in the incidence of neuroendocrine tumors, increasing investments, growing government initiatives, and the ongoing demand for neuroendocrine tumor treatments.

The neuroendocrine carcinoma market size is projected to experience robust growth in the coming years. It is predicted to expand to $2.31 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.2%. The anticipated growth during this period is driven by factors such as the rising incidence of cancer, an increasing number of product approvals, greater adoption of improved diagnostic imaging methods, the expansion of targeted therapies, and the growing availability of diagnosis and treatment options. Significant trends expected during the forecast period include progress in diagnostic technologies, advancements in imaging technologies, the development of targeted treatment approaches, improvements in neuroendocrine tumor management, and the evolution of targeted therapies and immunotherapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp

Which Industry Drivers Are Expected To Accelerate The Neuroendocrine Carcinoma Market From 2025 To 2029?

The expansion of targeted therapies is projected to advance the neuroendocrine carcinoma market in the future. These therapies are treatments designed to accurately pinpoint and disrupt the molecular processes or genetic alterations responsible for a disease, especially cancer. The demand for targeted therapies is rising due to factors such as their precision in treating specific genetic mutations, breakthroughs in personalized medicine, and enhanced patient outcomes with fewer side effects. Neuroendocrine carcinoma facilitates the development of targeted therapies that specifically address the tumor’s genetic and biochemical profiles, thereby improving treatment precision and effectiveness. For instance, in July 2023, a report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, showed that at the end of Q1 2023, there were 247 gene therapies in Phase II, and this number subsequently increased by 5% to reach 260 by the end of Q2. Therefore, the growth of targeted therapies is propelling the growth of the neuroendocrine carcinoma market.

What Are The Major Segments Identified In The Neuroendocrine Carcinoma Market?

The neuroendocrine carcinomamarket covered in this report is segmented –

1) By Type: Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Tumors; Pheochromocytoma; Medullary Thyroid Carcinoma

2) By Diagnostic Tools: Imaging; Biopsy; Serology

3) By Treatment: Chemotherapy; Radiotherapy; Surgery; Other Treatments

4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

5) By End-User: Hospitals; Clinics; Oncology Centers; Ambulatory Surgery Centers

Subsegments:

1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs); Small Intestinal Neuroendocrine Tumors; Gastric Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors

2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors; Gastrointestinal Carcinoid Tumors

3) By Pheochromocytoma: Adrenal Pheochromocytoma; Extra-Adrenal Paraganglioma

4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma; Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)

Which Key Trends Are Expected To Influence The Neuroendocrine Carcinoma Market In The Coming Years?

Leading companies active in the neuroendocrine carcinoma market are concentrating on developing advanced therapeutic approaches, such as targeted radiopharmaceutical therapy, with the goal of improving treatment accuracy and patient results. Targeted radiopharmaceutical therapy employs radioactive molecules engineered to specifically identify and deliver radiation to cancer cells, thereby minimizing adverse effects on healthy tissue. For instance, in September 2024, Abdera Therapeutics Inc., a Canada-based biotechnology company, was granted orphan drug designation by the Food and Drug Administration (FDA) for ABD-147 for addressing neuroendocrine carcinoma. This drug is formulated to selectively target tumors that exhibit the DLL3 protein, which is often found in elevated levels in aggressive neuroendocrine cancers, including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This designation provides substantial developmental benefits, encompassing tax credits for clinical trials and the possibility of market exclusivity, thereby positioning ABD-147 as a hopeful treatment in this particular oncology field.

Which Leading Companies Dominate The Neuroendocrine Carcinoma Market Share?

Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report

How Does The Neuroendocrine Carcinoma Market Perform Across Key Geographic Regions?

North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Neuroendocrine Carcinoma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21229&type=smp

Browse Through More Reports Similar to the Global Neuroendocrine Carcinoma Market 2025, By The Business Research Company

Neuroendocrine Tumor Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/neuroendocrine-tumor-treatment-global-market-report

Hepatocellular Carcinoma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hepatocellular-carcinoma-drugs-global-market-report

Unresectable Hepatocellular Carcinoma Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/unresectable-hepatocellular-carcinoma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795